(E)-3-(3-(4-adamantan-1-yl-phenoxy)acrylamido)benzoic acid 2-(dimethylamino)ethylester | 1373443-14-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-(3-(4-adamantan-1-yl-phenoxy)acrylamido)benzoic acid 2-(dimethylamino)ethylester
• 英文别名: 2-(dimethylamino)ethyl 3-[[(E)-3-[4-(1-adamantyl)phenoxy]prop-2-enoyl]amino]benzoate
• CAS: 1373443-14-1
• 化学式: C₃₀H₃₆N₂O₄
• 分子量: 488.627
• InChiKey: YTJMDIQMCHUZKC-ZRDIBKRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(1-金刚烷基)苯酚 在 lithium hydroxide monohydrate 、 potassium carbonate 、 N,N-二异丙基乙胺 、 三苯基膦 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 15.0h， 生成 (E)-3-(3-(4-adamantan-1-yl-phenoxy)acrylamido)benzoic acid 2-(dimethylamino)ethylester
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationship of (E)-Phenoxyacrylic Amide Derivatives as Hypoxia-Inducible Factor (HIF) 1α Inhibitors

  摘要：

  A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) la inhibitors. The present structure activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1 alpha under hypoxic conditions (IC50 = 0.12 mu M in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1 alpha accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-l alpha inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.

  DOI：

  10.1021/jm301419d

文献信息

• ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT
  申请人：Lee Kyeong

  公开号：US20130237542A1

  公开（公告）日：2013-09-12

  The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

  本发明涉及一种抑制HF-1活性的化合物，以及该化合物的制备方法和包含该化合物作为活性成分的药物组合物。本发明的化合物通过抑制HIF-1活性而不是通过非选择性细胞毒性表现出抗癌活性，HIF-1是在癌细胞生长和转移中起重要作用的转录因子。因此，根据本发明的化合物或其药用盐抑制HIF-1活性，因此可以用作固体肿瘤如结肠癌、肝癌、胃癌和乳腺癌的治疗剂。此外，根据本发明的化合物或其药用盐还可以用作糖尿病视网膜病变或关节炎的治疗剂的活性成分，当HIF-1诱导的VEGF表达增加时，这些疾病可能会恶化。
• Aryloxy phenoxy acrylic compound having HIF-1 inhibition activity, method for preparing same, and pharmaceutical composition containing same as an active ingredient
  申请人：Lee Kyeong

  公开号：US08940936B2

  公开（公告）日：2015-01-27

  The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

  本发明涉及一种抑制HF-1活性的化合物、其制备方法和包含其作为活性成分的药物组合物。本发明的化合物通过抑制在癌细胞生长和转移中起重要作用的转录因子HIF-1的活性，而不是通过非选择性细胞毒性来表现出抗癌活性。因此，根据本发明的化合物或其药学上可接受的盐抑制HIF-1的活性，因此可以用作固体肿瘤（如结肠癌、肝癌、胃癌和乳腺癌）的治疗剂。此外，根据本发明的化合物或其药学上可接受的盐可以用作治疗糖尿病视网膜病变或关节炎的活性成分，这些疾病可能会在HIF-1诱导的VEGF表达增加时变得更加严重。
• US8940936B2
  申请人：——

  公开号：US8940936B2

  公开（公告）日：2015-01-27
• Synthesis and Structure–Activity Relationship of (<i>E</i>)-Phenoxyacrylic Amide Derivatives as Hypoxia-Inducible Factor (HIF) 1α Inhibitors
  作者：Ravi Naik、Misun Won、Bo-Kyung Kim、Yan Xia、Hyun Kyung Choi、Guanghai Jin、Youngjin Jung、Hwan Mook Kim、Kyeong Lee

  DOI：10.1021/jm301419d

  日期：2012.12.13

  A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) la inhibitors. The present structure activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1 alpha under hypoxic conditions (IC50 = 0.12 mu M in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1 alpha accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-l alpha inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.